cfDNA reference standard for *EGFR* mutations, 3/18

March 2018—Horizon Discovery launched its EGFR Multiplex cfDNA Reference Standard. The cell line-derived *EGF*R multiplex cell-free DNA reference standard allows laboratories and assay developers to optimize, validate, and routinely monitor performance of polymerase chain reaction–based tests, next-generation sequencing, and other novel assays designed to detect *EGFR* mutations from cfDNA.

The reference standard covers 10 of the most clinically relevant mutations that predict responsiveness to EGFR tyrosine kinase inhibitors, including T790M, L858R, C797S, and E746-A750del. These variants have been carefully selected to represent a mix of different mutation types, such as single nucleotide polymorphisms and indels. It is supplied in a DNA fragment range of 160 base pairs, which is comparable to the DNA size found in real samples, and comes in a set of four vials, with allelic frequencies from five percent to 0.1 percent, along with a matched *EGFR* wild type, enabling determination of assay specificity, sensitivity, and limit of detection.

***Horizon Discovery**, 314-449-9251*